I have a fasta file with gene sequences - are there existing tools / pipelines that calculate & quantify the variable and conserved regions? Assuming that there has to be an accepted protocol / method for this but haven't found anything...
-
-
Are the sequences from one gene (or multiple genes)? Generally a multiple sequence alignment (MSA) will give you this information. -
the sequences are all from one gene...Comment
-
Look into clustalW (or clustal omega if these are protein sequences). T-coffee/MUSCLE/MAFFT are all programs that can be used (http://www.ebi.ac.uk/Tools/msa/) for alignments as well. You may need to download and run the programs locally if you have a large number of sequences.
What exactly are you looking for in terms of "calculate and quantify"?Comment
-
what I'm looking to do is take the reads from a sequencing run and 'ensure' (as best I can) that the correct target section was in fact amplified... I have run the reads through usearch against a database of target gene sequences - but I am trying to see what kind of variability may be expected by calculating the existing variability in the known / published gene sequences...Comment
-
If your data is still in the form of individual reads then you may want to use an NGS aligner (BBMap, bowtie2, BWA) to align them the gene (or genes?) region and create a BAM. Then you can use samtools/bcftools to call SNP's/get a consensus sequence for the gene(s).Comment
-
yeah, I aligned them w/ bwa, created a bam file and then viewed them in igv and the reads - or 54% of them - are aligning along the bacterial genome where the gene is located...
but since it is coming from a clinical sample I am trying to see what the variability is along the existing db of sequenced genes to have something to help put the alignment score into perspective... I think I'll just write a simple script to calculate the base abundance once muscle finishes aligning the existing sequences...Comment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...Yesterday, 11:01 AM -
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM
Comment